| Available data# | ||
| Sex | 2440 (99.96) | |
| Male | 1916 (78.5) | |
| Female | 524 (21.5) | |
| Age yrs | 2427 (99.43) | 67.3±9.4 |
| Body mass index kg·m−2 | 2394 (98.07) | 26.0±5.0 |
| Smoking status | 2337 (95.74) | |
| Current smoker | 565 (24.2) | |
| Ex-smoker | 1772 (75.8) | |
| Time since COPD diagnosis yrs | 2365 (96.89) | 8.9±7.6 |
| MRC dyspnoea score¶ | 2429 (99.51) | |
| 1 | 172 (7.1) | |
| 2 | 791 (32.6) | |
| 3 | 803 (33.1) | |
| 4 | 561 (23.1) | |
| 5 | 102 (4.2) | |
| FEV1 % pred | ||
| Pre-bronchodilator | 2279 (93.36) | 38.8±9.8 |
| Post-bronchodilator | 1510 (61.86) | 42.2±11.2 |
| FVC % pred | ||
| Pre-bronchodilator | 2195 (89.92) | 66.2±17.5 |
| Post-bronchodilator | 1458 (59.73) | 69.8±18.2 |
| FEV1/FVC % | ||
| Pre-bronchodilator | 2077 (85.09) | 47.1±10.4 |
| Post-bronchodilator | 1398 (57.27) | 48.3±11.4 |
| Reversibility+ | 1310 (53.67) | |
| % | 9.07±14.9 | |
| Yes | 199 (15.2) | |
| Type of current COPD maintenance treatment | 2431 (99.59) | |
| Only inhaled SABD§ | 50 (2.1) | |
| Only one inhaled LABDƒ | 272 (11.2) | |
| Only a combination of LABD## | 94 (3.9) | |
| Only inhaled glucocorticosteroids¶¶ | 39 (1.6) | |
| LABD plus inhaled glucocorticosteroids++ | 1634 (67.2) |
Data are presented as n (%) or mean±sd. COPD: chronic obstructive pulmonary disease; MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; SABD: short-acting bronchodilator; LABD: long-acting bronchodilator. #: n (%) of the total population of 2,441; ¶: MRC dyspnoea grade 1, “I only get breathless with strenuous exercise”; grade 2, “I get short of breath when hurrying on the level or up a slight hill”; grade 3, “I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level”; grade 4, “I stop for breath after walking 100 m or after a few minutes on the level”; grade 5, “ I am too breathless to leave the house”; +: reversibility was calculated for patients with available pre- and post-bronchodilator FEV1 data, and “yes” is defined as a post-bronchodilator increase in FEV1 of ≥200 mL and ≥12%; §: patients receiving only an inhaled short-acting β2-agonist (SABA) or an inhaled short-acting anticholinergic, or a fixed or free combination of inhaled SABA plus anticholinergic; ƒ: patients receiving only one LABD (inhaled long-acting β2-agonist (LABA), or oral LABA, or long-acting muscarinic antagonist (LAMA)) ± SABD ± methylxanthines; ##: patients receiving a combination of LABD (LABA or LAMA) ± SABD ± methylxanthines; ¶¶: patients receiving only inhaled glucocorticosteroids ± SABD; ++: patients receiving inhaled glucocorticosteroids plus LABA (inhaled or oral) and/or LAMA ± SABD ± methylxanthines.